Show simple item record

dc.contributor.authorMauschitz, Matthias M.
dc.contributor.authorVerzijden, Timo
dc.contributor.authorSchuster, Alexander K.
dc.contributor.authorElbaz, Hisham
dc.contributor.authorPfeiffer, Norbert
dc.contributor.authorKhawaja, Anthony
dc.contributor.authorLuben, Robert N.
dc.contributor.authorFoster, Paul J.
dc.contributor.authorRauscher, Franziska G.
dc.contributor.authorWirkner, Kerstin
dc.contributor.authorKirsten, Toralf
dc.contributor.authorJonas, Jost B.
dc.contributor.authorBikbov, Mukharram M.
dc.contributor.authorHogg, Ruth
dc.contributor.authorPeto, Tunde
dc.contributor.authorCougnard-Grégoire, Audrey
dc.contributor.authorBertelsen, Geir
dc.contributor.authorErke, Maja Gran
dc.contributor.authorTopouzis, Fotis
dc.contributor.authorGiannoulis, Dimitrios A.
dc.contributor.authorBrandl, Caroline
dc.contributor.authorHeid, Iris M.
dc.contributor.authorCreuzot-Garcher, Catherine P.
dc.contributor.authorGabrielle, Pierre-Henry
dc.contributor.authorHense, Hans-Werner
dc.contributor.authorPauleikhoff, Daniel
dc.contributor.authorBarreto, Patricia
dc.contributor.authorCoimbra, Rita
dc.contributor.authorPiermarocchi, Stefano
dc.contributor.authorDaien, Vincent
dc.contributor.authorHolz, Frank G.
dc.contributor.authorDelcourt, Cecile
dc.contributor.authorFinger, Robert P.
dc.date.accessioned2023-03-21T12:10:17Z
dc.date.available2023-03-21T12:10:17Z
dc.date.issued2022-11-07
dc.description.abstract<p><i>Background/aims</i> To investigate the association of commonly used systemic medications with prevalent age-related macular degeneration (AMD) in the general population. <p><i>Methods</i> We included 38 694 adults from 14 population-based and hospital-based studies from the European Eye Epidemiology consortium. We examined associations between the use of systemic medications and any prevalent AMD as well as any late AMD using multivariable logistic regression modelling per study and pooled results using random effects meta-analysis. <p><i>Results</i> Between studies, mean age ranged from 61.5±7.1 to 82.6±3.8 years and prevalence ranged from 12.1% to 64.5% and from 0.5% to 35.5% for any and late AMD, respectively. In the meta-analysis of fully adjusted multivariable models, lipid-lowering drugs (LLD) and antidiabetic drugs were associated with lower prevalent any AMD (OR 0.85, 95% CI=0.79 to 0.91 and OR 0.78, 95% CI=0.66 to 0.91). We found no association with late AMD or with any other medication. <p><i>Conclusion</i> Our study indicates a potential beneficial effect of LLD and antidiabetic drug use on prevalence of AMD across multiple European cohorts. Our findings support the importance of metabolic processes in the multifactorial aetiology of AMD.en_US
dc.identifier.citationMauschitz, Verzijden, Schuster, Elbaz, Pfeiffer, Khawaja, Luben, Foster, Rauscher, Wirkner, Kirsten, Jonas, Bikbov, Hogg, Peto, Cougnard-Grégoire, Bertelsen, Erke, Topouzis, Giannoulis, Brandl, Heid, Creuzot-Garcher, Gabrielle, Hense, Pauleikhoff, Barreto, Coimbra, Piermarocchi, Daien, Holz, Delcourt, Finger. Association of lipid-lowering drugs and antidiabetic drugs with age-related macular degeneration: A meta-analysis in Europeans. British Journal of Ophthalmology. 2022en_US
dc.identifier.cristinIDFRIDAID 2094766
dc.identifier.doi10.1136/bjo-2022-321985
dc.identifier.issn0007-1161
dc.identifier.issn1468-2079
dc.identifier.urihttps://hdl.handle.net/10037/28804
dc.language.isoengen_US
dc.publisherBMJ Journalsen_US
dc.relation.journalBritish Journal of Ophthalmology
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2022 The Author(s)en_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0en_US
dc.rightsAttribution 4.0 International (CC BY 4.0)en_US
dc.titleAssociation of lipid-lowering drugs and antidiabetic drugs with age-related macular degeneration: A meta-analysis in Europeansen_US
dc.type.versionacceptedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

Attribution 4.0 International (CC BY 4.0)
Except where otherwise noted, this item's license is described as Attribution 4.0 International (CC BY 4.0)